The 156,000ft² center will expand R&D and manufacturing capabilities for developing various technologies including PCR-based testing, nucleic acid sample preparation, protein purification and antibodies for enzyme-linked immunosorbent assay testing.
Thermo Fisher Scientific president and chief executive officer Marc Casper said the expanded R&D and manufacturing presence in Vilnius strengthens the company’s ability to serve the growing biotechnology community in Eastern Europe, particularly its research customers who rely on innovations in molecular biology to accelerate developments in diagnosing and treating disease.
"We now have a solid foundation from which we can continue to increase our depth of capabilities for high-growth life sciences markets in the region, from PCR-based products to our broader biosciences portfolio," Casper added.
In addition to developing scientific workforce in Lithuania, the company supports science education through a series of initiatives including internships and scholarships that provide students with practical experience and financial support.